Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01887015
Other study ID # CHU-0157
Secondary ID 2013-A00030-45
Status Completed
Phase Phase 4
First received June 24, 2013
Last updated March 26, 2015
Start date June 2013
Est. completion date March 2015

Study information

Verified date March 2015
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

To evaluate whether early application of nasal high flow oxygen therapy after extubation can reduce the incidence of postoperative hypoxemia (defined as a PaO2/FiO2 ratio <300) after abdominal surgery in patients with intermediate to high risk of postoperative pulmonary complications.


Description:

Postoperative hypoxemia complicates between 30 to 50% of patients after abdominal surgery. Loss of functioning alveolar units and development of atelectasis after abdominal surgery have been recognized as the underlying mechanisms responsible for postoperative hypoxemia. Supplemental Oxygen administration is therefore widely recommended after extubation in the postoperative period, especially in patients with high risk of postoperative respiratory complications. Although oxygen therapy is effective in preventing the vast majority of severe postoperative hypoxemia after extubation in surgical patients, respiratory failure may occur, thus requiring endotracheal intubation and mechanical ventilation or therapeutic use of non-invasive positive pressure ventilation (NPPV). In patients with postoperative hypoxemia (defined as patients with a PaO2/FiO2 ratio <300), application of NPPV was found to decrease the incidence of endotracheal intubation after abdominal surgery. Nevertheless, use of NPPV in the postoperative period is responsible for organizational constraints and increases healthcare utilization.

Nasal high flow cannula (NHFC) has been described as an attractive and well-tolerated method of non-invasive oxygen delivery. Previous studies have shown that NHFC generates a low level of positive airway pressure, increases end-expiratory lung volume and reduces airway resistance, thus contributing to a reduction in work of breathing. To date, however, no clinical trials have compared NHFC to standard oxygen therapy in the prevention of postoperative hypoxemia after abdominal surgery in patients with intermediate to high risk of postoperative pulmonary complications.

The primary objective of the study is to compare: 1- Standard oxygen therapy; 2- Nasal high flow oxygen therapy after extubation in patients with intermediate to high risk of postoperative pulmonary complications after abdominal surgery.

Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Planned or unplanned surgical procedures

- Abdominal or abdominal and thoracic surgery

- Expected duration =2 hours

- ARISCAT score =26 points

Exclusion Criteria:

- Age <18 years

- Body mass index >35 kg/m2

- Sleep apnea syndrome

- Patient refusal

- Pregnancy and/or lactation

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)


Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary percentage of patients who developed postoperative hypoxemia (defined as PaO2/FiO2 ratio <300) 1 hour after tracheal extubation (day 1) No
Secondary Postoperative gas exchange (PaO2, PaCO2) 1H after extubation and after surgery (at day 1) No
Secondary Need for supplemental oxygen therapy beyond postoperative day 1 (defined as arterial oxygen saturation by pulse oximetry (SpO2) <93% in room air) at day 1 No
Secondary Need for endotracheal intubation or non-invasive ventilation for postoperative acute respiratory failure (ARF) ARF (acute respiratory failure) is defined by one of the hypoxemic criteria (SpO2 <92% while breathing at least 10 L/min oxygen, PaO2 <60 mmHg on air or <80 mmHg while breathing any supplemental oxygen) and at least 1 of the following criteria: severe respiratory distress with dyspnea, accessory muscle recruitment and paradoxical abdominal or thoracic motion, respiratory rate >25 breaths/min, respiratory acidosis with pH <7.30 and PaCO2 > 50 mmHg. within the first 7 days after surgery No
Secondary Postoperative pulmonary complications (PPCs) PPCs(Postoperative pulmonary complications ) are scored using a grade scale ranging from 0 to 4, with grade 0 representing the absence of any complications and grade 1 through 4 representing successively the worse forms of complications. within the first 7 days after surgery No
Secondary Respiratory discomfort using a numerical rating scale (NRS) ranging from 0 (no discomfort) to 10 (maximum imaginable discomfort). Discomfort symptoms are assessed by evaluating dryness of the nose, mouth and throat. within the first 7 days after surgery No
See also
  Status Clinical Trial Phase
Completed NCT01362647 - Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit N/A
Not yet recruiting NCT06304493 - REMINDers for Incentive Spirometry in PACU (REMIND-IS in PACU) N/A
Not yet recruiting NCT05252234 - Post SARS-Cov-2 Disease Anesthesia Events